Search - tctmd.com

Displaying 161 - 180 of 236

Sort: Relevancy | Date

News Daily News

FDA Advisory Committee Rejects AngelMed Guardian Intracardiac Monitor

Todd Neale

March 17, 2016

News Daily News

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

Michael O'Riordan

March 16, 2016

News Daily News

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

Michael O'Riordan

March 14, 2016

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

Public Reporting of PCI Mortality: Debate Swirls Around What’s Fair, What’s Ethical

Todd Neale

March 06, 2016

News Daily News

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

Michael O'Riordan

February 23, 2016

News Daily News

Cardiologist Robert Califf Becomes New Commissioner of the FDA

L.A. McKeown

February 23, 2016

News Daily News

FDA Advisors Recommend Comprehensive, Long-Term Study of Leadless Pacemakers

Yael L. Maxwell

February 18, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

Study Pinpoints Predictors of New Conduction Abnormalities, Pacemaker With Sapien 3

L.A. McKeown

February 07, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Shelley Wood

January 18, 2016

News Daily News

Even a Little Exercise Yields Big Benefits, but Harm Unlikely at High Activity Levels

Michael O'Riordan

January 18, 2016

News Daily News

Radial-Access Associated with One-Third Less Bleeding in Rescue PCI After Fibrinolysis

Michael O'Riordan

December 20, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Daily News

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Michael O'Riordan

December 13, 2015

News Daily News

Good News, Bad News Week for Watchman LAA Occluder

Shelley Wood

November 12, 2015

News Industry News

FDA strengthens warning on NSAID labels

July 10, 2015

Advertisement

FDA Advisory Committee Rejects AngelMed Guardian Intracardiac Monitor

FDA Panel Overwhelmingly Supports Absorb Bioresorbable Stent

FDA Review of Absorb Bioresorbable Stent Does Not Tip Hand Ahead of Tomorrow’s Advisory Panel Meeting

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Public Reporting of PCI Mortality: Debate Swirls Around What’s Fair, What’s Ethical

Increased Risk of Device Thrombosis With Bioresorbable Scaffold, but Some Say Risks Can Be Mitigated

Cardiologist Robert Califf Becomes New Commissioner of the FDA

FDA Advisors Recommend Comprehensive, Long-Term Study of Leadless Pacemakers

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Study Pinpoints Predictors of New Conduction Abnormalities, Pacemaker With Sapien 3

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Even a Little Exercise Yields Big Benefits, but Harm Unlikely at High Activity Levels

Radial-Access Associated with One-Third Less Bleeding in Rescue PCI After Fibrinolysis

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Good News, Bad News Week for Watchman LAA Occluder

FDA strengthens warning on NSAID labels

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content